AN2 Therapeutics (ANTX) EBITDA (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of EBITDA data on file, last reported at -$10.6 million in Q1 2026.

• On a quarterly basis, EBITDA rose 8.55% year-over-year to -$10.6 million in Q1 2026; TTM through Mar 2026 was -$37.1 million, a 25.8% increase from a year earlier, with the FY2025 full-year figure at -$38.1 million, up 32.89% from the prior year.
• EBITDA for Q1 2026 stood at -$10.6 million, down from -$9.3 million in the prior quarter.
• Over the last five years, EBITDA for ANTX reached as high as -$7.2 million in Q2 2025 and fell as low as -$18.8 million in Q4 2023.
• Historically, EBITDA has averaged -$12.8 million across 5 years, with a median of -$11.8 million in 2022.
• Across the five-year window, EBITDA slumped 274.78% in 2022 and soared 54.56% in 2025, its largest moves.
• Year by year, EBITDA stood at -$12.5 million in 2022, then sank by 50.81% to -$18.8 million in 2023, then jumped by 54.3% to -$8.6 million in 2024, then decreased by 8.35% to -$9.3 million in 2025, then dropped by 13.26% to -$10.6 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$10.6 million in Q1 2026, -$9.3 million in Q4 2025, and -$10.0 million in Q3 2025.